The authorization of an Alzheimer’s drug developed by the pharmaceutical group Eli Lilly could take place this year in the United States, after the publication Monday of the complete results of a large clinical trial.
These confirmed the ability of the treatment, donanemab, to slow the progression of the disease in patients, especially when taken very early. But some experts remain cautious about this new treatment, the benefits of which remain “modest“and which carries potentially dangerous side effects, such as cerebral edema or hemorrhage. Three deaths of participants in the clinical trial are probably linked to the treatment, according to the study.
2023-07-17 20:29:25
#authorization #2nd #innovative #treatment #Alzheimers #approaching #United #States
